guanfacine has been researched along with Acute Myelogenous Leukemia in 1 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, H | 1 |
| Luo, G | 1 |
| Hu, X | 1 |
| Xu, G | 1 |
| Wang, T | 1 |
| Liu, M | 1 |
| Qiu, X | 1 |
| Li, J | 2 |
| Fu, J | 1 |
| Feng, B | 1 |
| Tu, Y | 1 |
| Kan, W | 1 |
| Wang, C | 1 |
| Xu, R | 1 |
| Zhou, Y | 1 |
| Yang, J | 1 |
1 other study available for guanfacine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia.
Topics: Animals; CCAAT-Enhancer-Binding Protein-alpha; Female; fms-Like Tyrosine Kinase 3; Guanfacine; Leuke | 2023 |